Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Summary

RATIONALE: Midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Midostaurin may help azacitidine kill more cancer cells by making the cancer cells more sensitive to the drug. PURPOSE: This phase I/II trial is studying the side effects and best dose of midostaurin when given together with azacitidine and to see how well it works in treating elderly patients with acute myelogenous leukemia.

Timeline

Start

2009-07

Primary completion

2016-09-08

Completion

2017-05-05

Publications

• Background Tomlinson BK, Gallogly MM, Kane DM, Metheny L, Lazarus HM, William BM, Craig MD, Levis MJ, Cooper BW. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):226-233.e1. doi: 10.1016/j.clml.2019.10.018. Epub 2019 Nov 6.

Drugs

Indications